BioSpace News Archive

Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles, an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.

Autobahn Therapeutics today announced positive topline results from a first-in-human Phase 1 clinical study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of ABX-002 in healthy volunteers.

IMUNON, Inc. announces that the Company will host a conference call at 10:00 a.m. ET on Tuesday, November 14, 2023 to discuss financial results for the third quarter and nine-months ended September 30, 2023.

LAPIX Therapeutics, Inc. today announced that the first participants have been dosed in the Phase 1 study of the Company’s LPX-TI641therapy.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced that effective November 1, its UroShield actuators are eligible for reimbursement on NHS Prescription Services’ Drug Tariff.

Legend Biotech Corporation will host a conference call for investors at 8:00am Eastern Time on Monday, November 20, 2023, to review third-quarter results.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.

Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. ( NASDAQ:JAGX ) family company, today issued a reminder that the company is hosting a virtual educational webinar with leading gastroenterologists and nutrition experts on intestinal failure associated with the rare diseases short bowel syndrome (SBS) and microvillus inclusion disease (MVID) on November 8, 2023 from 1:00 PM to 2:30 PM.

NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation Monarch eTNS System™ (Monarch 2.0).

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the third quarter ended September 30, 2023.